<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00182975</url>
  </required_header>
  <id_info>
    <org_study_id>AG0047</org_study_id>
    <secondary_id>R01AG020076</secondary_id>
    <nct_id>NCT00182975</nct_id>
  </id_info>
  <brief_title>Effects of Dehydroepiandrosterone (DHEA) in Humans</brief_title>
  <official_title>Is DHEA Replacement Beneficial?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Aging (NIA)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether bringing back the DHEA levels of older
      persons to the young range produces beneficial effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DHEA and DHEA sulfate (DHEAS) plasma concentrations peak at about 20 years of age and decline
      rapidly and markedly after age 25 yr. DHEA is a PPAR-alpha activator. PPAR-alpha plays major
      roles in regulating lipid metabolism and controlling inflammation. DHEA also appears to have
      anabolic effects on muscle and bone. The study is designed to determine the effects of 12
      months of DHEA replacement in 65-75 year old women and men on (a) truncal and visceral fat,
      (b) insulin resistance and serum triglycerides, (c) muscle mass and strength, (d) bone
      mineral density, (e) chronic inflammation, (f) arterial-endothelium-dependent vasodilation,
      and (g) sense of well being.

      The specific aims of this study are to test the hypotheses that 12 months of DHEA replacement
      will (a) Result in significant decreases in truncal and visceral fat by shifting metabolism
      to fat oxidation and increasing energy wastage; (b) Decrease insulin resistance and decrease
      serum triglycerides; (c) Increase muscle mass and strength, by decreasing catabolic stimuli
      and increasing anabolic stimuli; (d) Increase bone mineral density by increasing anabolic
      stimuli and decreasing catabolic stimuli; (e) Reduce chronic inflammation and decrease
      pro-inflammatory cytokine production by peripheral blood mononuclear cells; (f) Improve
      arterial endothelium dependent vasodilation; and (g) Improve general sense of well being.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>body composition (e.g. truncal fat and visceral fat), insulin resistance and serum triglycerides, muscle mass and strength</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>bone mineral density, arterial-endothelium dependent vasodilatation, sense of well being, RMR (Resting Metabolic Rate), TEF (Thermal Effect of Food)</measure>
  </secondary_outcome>
  <enrollment type="Actual">142</enrollment>
  <condition>Aging</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHEA replacement</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  65 to 75 years old

          -  Physically healthy

          -  Non-smoker

          -  On stable medications for at least 6 months

          -  Stable body weight for the past year

        Exclusion Criteria:

          -  Serious active medical problems

          -  Hormone therapy

          -  Abnormal PSA (prostate specific antigen) in men
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John O. Holloszy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hansen PA, Han DH, Nolte LA, Chen M, Holloszy JO. DHEA protects against visceral obesity and muscle insulin resistance in rats fed a high-fat diet. Am J Physiol. 1997 Nov;273(5 Pt 2):R1704-8.</citation>
    <PMID>9374813</PMID>
  </reference>
  <reference>
    <citation>Han DH, Hansen PA, Chen MM, Holloszy JO. DHEA treatment reduces fat accumulation and protects against insulin resistance in male rats. J Gerontol A Biol Sci Med Sci. 1998 Jan;53(1):B19-24.</citation>
    <PMID>9467418</PMID>
  </reference>
  <reference>
    <citation>Villareal DT, Holloszy JO, Kohrt WM. Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. Clin Endocrinol (Oxf). 2000 Nov;53(5):561-8.</citation>
    <PMID>11106916</PMID>
  </reference>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>August 21, 2008</last_update_submitted>
  <last_update_submitted_qc>August 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2008</last_update_posted>
  <keyword>Metabolic syndrome</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

